Opinion|Videos|February 25, 2025
Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice
Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you talk about switching from dupilumab and other RWD with IL-13 agents in AD?
Advertisement
Related to this article
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
5